Lipid nanoparticle composition

A compound of Formula (I):

• or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
• G1 and G2 are each independently a bond, C2-C12 alkylene, or C2-C12 alkenylene, wherein one or more —CH2— in the alkylene or alkenylene is optionally replaced by —O—;
• L1 is —OC(═O)R1, —C(═O)OR1, —OC(═O)OR1, —C(═O)R1, —OR1, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc, —NRaC(═O)OR1, —SC(═S)R1, —C(═S)SR1, —C(═S)R1, —CH(OH)R1, —P(═O)(ORb)(ORc), —(C6-C10 arylene)-R1, -(6- to 10-membered heteroarylene)-R1, or R1;
• L2 is —OC(═O)R2, —C(═O)OR2, —OC(═O)OR2, —C(═O)R2, —OR2, —S(O)xR2, —S—SR2, —C(═O)SR2, —SC(═O)R2, —NRdC(═O)R2, —C(═O)NReRf, —NRdC(═O)NReRf, —OC(═O)NReRf, —NRdC(═O)OR2, —SC(═S)R2, —C(═S)SR2, —C(═S)R2, —CH(OH)R2, —P(═O)(ORe)(ORf), —(C6-C10 arylene)-R2, -(6- to 10-membered heteroarylene)-R2, or R2;
• R1 and R2 are each independently C6-C32 alkyl or C6-C32 alkenyl;
• Ra, Rb, Rd, and Re are each independently H, C1-C24 alkyl, or C2-C24 alkenyl;
• Rc and Rf are each independently C1-C32 alkyl or C2-C32 alkenyl;
• G3 is C2-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, or C3-C8 cycloalkenylene;
• R3 is —N(R4)R5;
• R4 is C3-C8 cycloalkyl, C3-C8 cycloalkenyl, 4- to 8-membered heterocyclyl, or C6-C10 aryl;
• and R4 is unsubstituted or substituted with one or more hydroxyl, halogen, unsubstituted C1-C6 alkyl, unsubstituted aryl, or oxo;
• R5 is C1-C12 alkyl or C3-C8 cycloalkyl;
• and R5 is unsubstituted, substituted with one or more hydroxyl, or substituted with one or more hydroxyl and one or more oxo;
• x is 0, 1 or 2;
• and
• wherein, unless otherwise specified, each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, and heteroarylene is independently optionally substituted.